AbbVie’s ABBV stock has risen 11.5% in the past month, mainly due to its beat-and-raise performance in the second quarter.

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 3 clinical study ...

AbbVie and Genmab’s epcoritamab has shown promise as part of a combination treatment for relapsed or refractory follicular ...

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

AbbVie Inc.'s Q2 2025 results showcase Skyrizi & Rinvoq's growth, strong finances, and a promising pipeline. Click for my ...

Construction on the site will begin in the fall and is expected to be finished by 2027. North Chicago is already home to ...

AbbVie (ABBV) announced a $195 million investment in its North Chicago manufacturing facility to boost domestic API ...

AbbVie will invest $195M to expand API manufacturing at its North Chicago plant, boosting U.S. pharmaceutical innovation, ...

AbbVie is investing $195m to strengthen domestic active pharmaceutical ingredient (API) production within the US, with the ...

Shares of AbbVie Inc. ABBV rose 1.42% to $201.47 Wednesday, on what proved to be an all-around positive trading session for ...

AbbVie said on Thursday its tariff exposure is not expected to exceed that of rivals, and raised its 2025 profit forecast citing strong sales of its newer immunology drugs Skyrizi and Rinvoq.